JP2017523188A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017523188A5 JP2017523188A5 JP2017504752A JP2017504752A JP2017523188A5 JP 2017523188 A5 JP2017523188 A5 JP 2017523188A5 JP 2017504752 A JP2017504752 A JP 2017504752A JP 2017504752 A JP2017504752 A JP 2017504752A JP 2017523188 A5 JP2017523188 A5 JP 2017523188A5
- Authority
- JP
- Japan
- Prior art keywords
- dlbcl
- use according
- modification
- amino acid
- bcl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462032430P | 2014-08-01 | 2014-08-01 | |
| US62/032,430 | 2014-08-01 | ||
| US201562119668P | 2015-02-23 | 2015-02-23 | |
| US62/119,668 | 2015-02-23 | ||
| US201562127484P | 2015-03-03 | 2015-03-03 | |
| US62/127,484 | 2015-03-03 | ||
| PCT/US2015/043300 WO2016019341A1 (en) | 2014-08-01 | 2015-07-31 | Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017523188A JP2017523188A (ja) | 2017-08-17 |
| JP2017523188A5 true JP2017523188A5 (enExample) | 2018-09-13 |
Family
ID=55179406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017504752A Pending JP2017523188A (ja) | 2014-08-01 | 2015-07-31 | Ｂｔｋ阻害剤を伴う治療に対するｄｌｂｃｌの応答を予測するためのバイオマーカー |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20160032404A1 (enExample) |
| EP (1) | EP3185870A4 (enExample) |
| JP (1) | JP2017523188A (enExample) |
| KR (1) | KR20170042614A (enExample) |
| CN (1) | CN106714804A (enExample) |
| AU (1) | AU2015296010A1 (enExample) |
| BR (1) | BR112017001677A2 (enExample) |
| CA (1) | CA2955744A1 (enExample) |
| IL (1) | IL250221A0 (enExample) |
| MX (1) | MX2017001302A (enExample) |
| RU (1) | RU2017106794A (enExample) |
| SG (1) | SG11201700774UA (enExample) |
| WO (1) | WO2016019341A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2350075T1 (sl) | 2008-09-22 | 2014-06-30 | Array Biopharma, Inc. | Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji |
| CN102264736B (zh) | 2008-10-22 | 2013-08-14 | 阵列生物制药公司 | 作为TRK激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物 |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| BR122019024201B1 (pt) | 2010-05-20 | 2021-08-03 | Array Biopharma Inc | Composto macrocíclico como inibidores de trk quinase, seu uso, e composição farmacêutica |
| MX380504B (es) | 2010-06-03 | 2025-03-12 | Pharmacyclics Llc | El uso de inhibidores de la tirosina quinasa de bruton (btk). |
| HK1206073A1 (en) | 2012-07-24 | 2015-12-31 | 药品循环有限责任公司 | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
| WO2016071770A2 (en) * | 2014-11-05 | 2016-05-12 | Janssen Pharmaceutica Nv | Biological markers for identifying ibrutinib resistance in patients having mantle cell lymphoma and methods of using the same |
| TWI746426B (zh) | 2014-11-16 | 2021-11-21 | 美商亞雷生物製藥股份有限公司 | (S)-N-(5-((R)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺硫酸氫鹽結晶型 |
| EP3892302B8 (en) | 2015-04-06 | 2023-10-18 | Janssen Pharmaceutica NV | Compositions containing ibrutinib |
| EP3368039A1 (en) | 2015-10-26 | 2018-09-05 | The Regents of The University of Colorado, A Body Corporate | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| UA125025C2 (uk) | 2016-04-04 | 2021-12-29 | Локсо Онколоджі, Інк. | Способи лікування дитячих ракових захворювань |
| UA125026C2 (uk) | 2016-04-04 | 2021-12-29 | Локсо Онколоджі, Інк. | РІДКІ КОМПОЗИЦІЇ (S)-N-(5-((R)-2-(2,5-ДИФТОРФЕНІЛ)ПІРОЛІДИН-1-ІЛ)ПІРАЗОЛО[1,5-a]ПІРИМІДИН-3-ІЛ)-3-ГІДРОКСИПІРОЛІДИН-1-КАРБОКСАМІДУ |
| MX392604B (es) | 2016-05-18 | 2025-03-24 | Array Biopharma Inc | Procesos para la preparacion de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidin-1-carboxamida y sales del mismo. |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| US11085039B2 (en) | 2016-12-12 | 2021-08-10 | xCella Biosciences, Inc. | Methods and systems for screening using microcapillary arrays |
| EP3551745A4 (en) * | 2016-12-12 | 2020-07-15 | Xcella Biosciences, Inc. | SCREENING METHODS AND SYSTEMS USING MICROCAPILLARY NETWORKS |
| CN110382439B (zh) | 2016-12-30 | 2026-07-21 | 埃克切拉生物科学公司 | 多级样品回收系统 |
| JOP20190213A1 (ar) * | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| JP7321101B2 (ja) | 2017-06-08 | 2023-08-04 | エンリヴェックス セラピューティクス アールディーオー リミテッド | 癌治療のための治療的アポトーシス細胞 |
| CZ2017787A3 (cs) | 2017-12-08 | 2019-06-19 | Zentiva, K.S. | Farmaceutické kompozice obsahující ibrutinib |
| KR102844084B1 (ko) * | 2018-06-15 | 2025-08-07 | 얀센 파마슈티카 엔브이 | 이브루티닙을 포함하는 제형/조성물 |
| GB2577909B (en) * | 2018-10-10 | 2020-11-18 | Symetrica Ltd | Gamma-ray spectrum classification |
| JP2022513666A (ja) * | 2018-11-30 | 2022-02-09 | ヤンセン バイオテツク，インコーポレーテツド | 濾胞性リンパ腫の治療方法 |
| DK3890876T3 (da) | 2018-12-06 | 2024-07-22 | Xcella Biosciences Inc | Lateral påfyldning af mikrokapillære arrays |
| WO2021087044A1 (en) * | 2019-10-30 | 2021-05-06 | Celgene Corporation | Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma |
| CA3156776A1 (en) | 2019-11-08 | 2021-05-14 | xCella Biosciences, Inc. | Apparatus and methods for laser-based single cell recovery from microcapillary arrays |
| CA3209784A1 (en) * | 2021-02-03 | 2022-08-11 | Curis Inc. | Biomarkers for fimepinostat therapy |
| MX2023014435A (es) | 2021-06-04 | 2024-03-08 | Janssen Pharmaceutica Nv | Inhibidores de la tirosina quinasa de bruton y métodos de su uso. |
| MX2023015147A (es) * | 2021-06-30 | 2024-04-01 | Janssen Pharmaceutica Nv | Inhibidores de la tirosina quinasa de bruton y métodos de su uso. |
| US20230010803A1 (en) * | 2021-06-30 | 2023-01-12 | Janssen Pharmaceutica Nv | Treatments for diffuse large b-cell lymphoma |
| JP7423090B2 (ja) * | 2022-04-07 | 2024-01-29 | 学校法人藤田学園 | 不明熱患者のｂ細胞リンパ腫診断補助キットおよび情報提供方法 |
| KR20260079677A (ko) * | 2023-10-09 | 2026-06-02 | 브리스톨-마이어스 스큅 컴퍼니 | 약물에 대한 림프종의 반응성을 예측하는 방법 및 림프종을 치료하는 방법 |
| JP7696987B1 (ja) | 2023-12-22 | 2025-06-23 | 東洋鋼鈑株式会社 | 遺伝子変異を検出する方法 |
| JP7698850B1 (ja) | 2023-12-22 | 2025-06-26 | 東洋鋼鈑株式会社 | 遺伝子変異評価用キット |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX380504B (es) * | 2010-06-03 | 2025-03-12 | Pharmacyclics Llc | El uso de inhibidores de la tirosina quinasa de bruton (btk). |
| CA2841142C (en) * | 2010-06-23 | 2020-12-15 | Ryan D. Morin | Biomarkers for non-hodgkin lymphomas and uses thereof |
| US20140303191A1 (en) * | 2011-10-19 | 2014-10-09 | Pharmacyclics, Inc. | Use of inhibitors of bruton's tyrosine kinase (btk) |
| JP2014532658A (ja) * | 2011-10-28 | 2014-12-08 | セルジーン アヴィロミクス リサーチ， インコーポレイテッド | ブルトン型チロシンキナーゼ疾患または障害を治療する方法 |
| MA37711A1 (fr) * | 2012-06-04 | 2017-05-31 | Pharmacyclics Inc | Formes cristallines d'un inhibiteur de tyrosine kinase de bruton |
| HK1206073A1 (en) * | 2012-07-24 | 2015-12-31 | 药品循环有限责任公司 | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
| WO2014110114A1 (en) * | 2013-01-10 | 2014-07-17 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
-
2015
- 2015-07-31 BR BR112017001677-0A patent/BR112017001677A2/pt not_active Application Discontinuation
- 2015-07-31 MX MX2017001302A patent/MX2017001302A/es unknown
- 2015-07-31 SG SG11201700774UA patent/SG11201700774UA/en unknown
- 2015-07-31 CN CN201580049596.7A patent/CN106714804A/zh active Pending
- 2015-07-31 AU AU2015296010A patent/AU2015296010A1/en not_active Abandoned
- 2015-07-31 CA CA2955744A patent/CA2955744A1/en not_active Abandoned
- 2015-07-31 JP JP2017504752A patent/JP2017523188A/ja active Pending
- 2015-07-31 KR KR1020177005365A patent/KR20170042614A/ko not_active Withdrawn
- 2015-07-31 EP EP15828160.0A patent/EP3185870A4/en not_active Withdrawn
- 2015-07-31 RU RU2017106794A patent/RU2017106794A/ru not_active Application Discontinuation
- 2015-07-31 WO PCT/US2015/043300 patent/WO2016019341A1/en not_active Ceased
- 2015-07-31 US US14/815,921 patent/US20160032404A1/en not_active Abandoned
-
2017
- 2017-01-22 IL IL250221A patent/IL250221A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017106794A (ru) | Биомаркеры для прогнозирования ответа двккл на лечение с использованием ингибитора втк | |
| CY1121873T1 (el) | Θεραπευτικη αντιμετωπιση του καρκινου | |
| Wang et al. | Gene expression profiling identifies IRF4-associated molecular signatures in hematological malignancies | |
| EA201992063A1 (ru) | СВЯЗЫВАЮЩИЕ ErbB-2 И ErbB-3 БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА ДЛЯ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ КЛЕТОК, КОТОРЫЕ СОДЕРЖАТ СЛИТЫЙ ГЕН NRG-1 | |
| MX2017015962A (es) | Uso de exosomas para el tratamiento de enfermedades. | |
| MY185845A (en) | Icos binding proteins | |
| BR112016029713A8 (pt) | uso de uma carboximetilcelulose reticulada e uso de um agente gelificante | |
| WO2017116817A3 (en) | Testing of medicinal drugs and drug combinations | |
| EP2568996A4 (en) | INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC AND ANTIBODY COMPOSITIONS IN CONNECTION WITH PROTEIN FRAGMENTS OF PHENYLALANYL BETA-TRNA SYNTHETASES | |
| WO2017027571A8 (en) | Mechanism of resistance to bet bromodomain inhibitors | |
| MX2015016304A (es) | Proteinas de union al antigeno del receptor de oncostatina m. | |
| EA201790504A1 (ru) | Монослой мононуклеарных клеток периферической крови или клеток костного мозга и его применение | |
| BR112019004911A2 (pt) | oligonucleotídeos modificados e métodos de uso | |
| EA202092156A1 (ru) | Модифицированные олигонуклеотиды и способы применения в лечении таупатий | |
| MY173804A (en) | Stable polypeptides binding to human complement c5 | |
| WO2018026969A3 (en) | Plazomicin antibodies and methods of use | |
| TWD195924S (zh) | 寶石 | |
| BR112018076287A2 (pt) | métodos e composições para o tratamento de doença celíaca, sensibilidade ao glúten não celíaca e doença celíaca refratária | |
| JP2015504432A5 (enExample) | ||
| CO2019002853A2 (es) | Composiciones de tesofensina | |
| WO2015168607A3 (en) | Ceacam5 peptides for crohn's disease | |
| JP2016521130A5 (enExample) | ||
| EP4328245A3 (en) | Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations | |
| Ling et al. | Re: Gut microbiota depletion from early adolescence in mice: Implications for brain and behavior | |
| WO2016096640A3 (en) | Anti-cxcl12 antibody molecules and their uses |